Navigation Links
Diabetes & Obesity Drug Development Pipeline Review, 2016
Date:12/6/2016

LONDON, Dec. 6, 2016 /PRNewswire/ -- Diabetes & Obesity Drug Development Pipeline Review, 2016

Summary

The diabetes and obesity disease cluster is currently dominated by therapeutics indicated for type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), and the majority of the pipeline, in terms of both quantity and quality of products, is attributable to these indications. While products indicated for obesity do not currently have a large market presence, there are a large number of these products in the pipeline, with the majority in early stages of development.

The combined therapy area of diabetes and obesity presents a strong pipeline, accounting for a large proportion of the overall metabolic disorders therapy area. The majority of products are small molecules and biologics, which reflects the overall pharmacotherapeutic market trend.

An increasing pipeline presence for obesity-indicated products and overwhelming global media interest highlight the relevance of this indication and its future potential global revenues. However, the number of pharmacotherapeutic products for obesity is dwarfed by diabetes-indicated products. Given the status of obesity as a risk factor for T2DM, it is likely that the T2DM pipeline will continue to grow with the rising obesity incidence.

Scope

- Which companies are the most active within the pipeline for diabetes and obesity?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared with pharmaceutical companies?
- What are the most important R&D milestones and data publications to have occurred in this disease area?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication.
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each.
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these.
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration.

Download the full report: https://www.reportbuyer.com/product/4411872/

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/diabetes--obesity-drug-development-pipeline-review-2016-300374103.html


'/>"/>
SOURCE ReportBuyer
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania
2. Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes
3. Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance
4. GlucoMen Launch App to Help Improve Diabetes Control
5. Health Diagnostic Laboratory, Inc. Announces Diabetes Prevention & Management Panel for Early Detection and Treatment of Disease
6. Metabolic Solutions Development Company announces publication of data describing potential for new drugs to maintain pancreatic beta-cells in treating diabetes
7. From Autism to Diabetes to Parkinsons Disease: Pew Funds 22 Early-Career Scientists to Take Calculated Risks
8. Intarcia Supports American Diabetes Association Call For Independent Review Of Incretin-Based Therapies
9. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
10. JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes
11. New Data on Islet Autoantibodies in Young Children Defines Early Type 1 Diabetes Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2018)... ... ... Commissioner Gottlieb’s FDA:, Analysis of First Year and a Look Ahead, **An ... , Under Commissioner Scott Gottlieb, changes at the FDA have come thick ... hurt. , And Gottlieb is just getting started. , Mark the calendar for Thursday, ...
(Date:8/7/2018)... ... , ... Braun Ambulances is honored to announce their attendance at FRI 2018. ... Dallas, Texas. Braun Ambulances will have four units on display at the conference and ... International (FRI) is the International Association of Fire Chiefs’ (IAFC) annual event; the conference ...
(Date:8/7/2018)... RAPIDS, Mich. (PRWEB) , ... August 07, 2018 ... ... the addition of Joe Morehouse, DO, to its growing team of eye care ... implants for astigmatism, and traditional intraocular lenses, as well as treating patients for ...
Breaking Medicine Technology:
(Date:8/15/2018)... ... August 15, 2018 , ... Today David Hyde Apparel debuts the first, fully ... out of a desire for confidence and comfort year-round, the new shirt leverages a ... in the hottest, most humid of climates. , The brainchild of two recent University ...
(Date:8/15/2018)... ... 2018 , ... Trumpet Behavioral Health (“Trumpet”) is pleased to ... Analysis in Practice, one of the leading journals in the field of applied ... for Trumpet, leading the company’s research clinical standards and training initiatives. , Behavior ...
(Date:8/14/2018)... ... August 14, 2018 , ... Kathy Mills Chang, the ... Connect User Conference. The ChiroTouch Conference is a one-day learning event hosted in ... is ecstatic to have Kathy Mills Chang lead the conference. Kath Mills Chang ...
(Date:8/14/2018)... ... 2018 , ... Health & hygiene ranked eighth out of 15 ... study of brands based on emotions. In the U.S., Olay again topped the industry, ... health & hygiene industry were: Listerine, Nivea, Gillette, Colgate, Head & Shoulders, Pantene and ...
(Date:8/14/2018)... (PRWEB) , ... August 14, 2018 , ... ... investment in the Recreational Group, a leading provider of residential and commercial recreational ... turf and sports surfacing industry, with products used across a wide range of ...
Breaking Medicine News(10 mins):